Business Wire49 分钟
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, is saddened to ...